When it comes to keeping the newborn brain healthy, taking steps to mitigate risk before birth may be critical. In ongoing investigations, clinical researchers from the Brigham are exploring whether a mother’s pomegranate juice intake during pregnancy can have a protective effect.
Some newborns, such as those with intrauterine growth restriction (IUGR) — a condition in which an unborn baby doesn’t reach a normal weight in the womb — are at heightened risk of brain damage. Being able to intervene before birth to aid in protecting the newborn brain may prevent the often-devastating effects of brain injury. In a recent paper in PLOS ONE, the Brigham team presented its preliminary findings from a clinical trial of expectant mothers whose babies were diagnosed with IUGR. The exploratory study, supported in part by an unrestricted gift from POM Wonderful, shows promise, with evidence of better brain development and brain connectivity in infants born to mothers who consumed pomegranate juice daily. A second, larger clinical trial is currently underway at the Brigham to validate these findings.
In cases of IUGR, a baby in the womb is measuring small for its gestational age often because of issues with the placenta, which brings oxygen and nutrients to the growing fetus. The process of birth
itself can further decrease blood flow or oxygen to the baby, including to the baby’s brain. If this is very severe, it can result in a serious, potentially fatal condition called hypoxic-ischemic injury.
Polyphenols are part of a class of antioxidants found in many foods and beverages, including nuts, berries, red wine and teas. Pomegranate juice is a particularly rich source of these compounds. Polyphenols are known to cross the blood-brain barrier, and studies in preclinical models have demonstrated protective effects against neurodegenerative diseases. To date, no clinical studies had evaluated the potential effects of giving pregnant women pomegranate juice to safeguard the brains of at-risk newborns.
“Our study provides preliminary evidence suggesting potential protective effects for newborns exposed to pomegranate juice while in utero,” said senior author Terrie Inder, MBCHB, chair of the Department of Pediatric Newborn Medicine. “These findings warrant continued investigation into the potential neuroprotective effects of polyphenols in at-risk newborns, such as those with hypoxic-ischemic injury.”
The current randomized, controlled, double-blinded study enrolled 78 mothers from Barnes-Jewish Hospital obstetric clinic in St. Louis with IUGR diagnosed at 24–43 weeks’ gestation. Women were randomized to receive 8 ounces of pomegranate juice daily or a taste/calorie-matched placebo that was polyphenol-free. Women drank the juice daily from enrollment until delivery. The team measured several aspects of brain development and injury, including infant brain structure, minute change and functional connectivity.
While the team did not observe differences in brain macrostructure, they did find regional differences in white matter microstructure and functional connectivity.
“These measures tell us about how the brain is developing functionally,” said Inder. “We saw no difference in brain growth and baby growth, but we did see improvement in cabling network and brain development measured by synchronous blood flow and visual development of the brain.”
The authors note that the findings warrant the need for a larger, rigorously designed clinical trial to allow continued investigation into the potential neuroprotective effects of polyphenols. Such a study is now underway at the Brigham.
“We plan to continue investigating these exciting findings,” said Inder. “While the preliminary evidence shows promise, additional study and replication is needed.”